CureLab Oncology Patents Groundbreaking Wound-Healing Therapy

BOSTON, June 27, 2024 — CureLab Oncology, a clinical-stage biotechnology firm, has made significant strides in the field of wound care by filing a groundbreaking patent application for a new therapy designed to expedite wound healing. This innovative treatment leverages a p62/SQSTM1 DNA plasmid, representing a promising advancement in both acute and chronic wound management. The technology aims to address critical needs by enhancing healing outcomes, cutting healthcare costs, and potentially transforming standard treatment protocols.

The newly patented therapy utilizes the distinct attributes of the p62 plasmid to hasten the natural healing process, diminish inflammation, and avert complications such as sepsis, infection, tissue damage, and scarring. Preclinical animal studies have shown the treatment's efficacy across various wound types, including lacerations, burns, diabetic ulcers, and pressure sores.

"This patent application is a significant achievement for CureLab Oncology and highlights our dedication to developing breakthrough treatments for major medical issues," stated Alexander Shneider, Ph.D., CEO of CureLab Oncology. "Millions of people worldwide suffer from chronic and acute wounds, and our p62-based therapy has the potential to drastically change the way we manage these challenging conditions."

The global wound care market is expected to grow significantly, projected to reach USD 37.08 billion by 2032, with a compound annual growth rate (CAGR) of 7.5% from 2024 to 2032. This growth is driven by the increasing prevalence of chronic diseases such as diabetes, an aging population, and advancements in wound care technology.

"Our strategy for patenting this wound-healing product mirrors the successful approach we've taken with other therapies," said Ilya Lapshin, general counsel for CureLab Oncology. "By initially filing a provisional patent application in the United States and then seeking worldwide protection, we aim to secure robust intellectual property rights for this innovative treatment."

Elenagen: CureLab's Lead Investigational Compound

CureLab’s principal investigational drug, known as Elenagen, is an experimental DNA therapy consisting of a circular DNA plasmid that carries a gene encoding the human protein p62/SQSTM1. Clinical trials conducted outside the U.S. have shown Elenagen to have a favorable safety profile and statistically significant clinical benefits for cancer patients, enhancing the effectiveness of chemotherapy. Experimental results also indicate that Elenagen can reduce chronic inflammation, exhibit anti-aging properties, and stimulate an immune response against tumors.

About CureLab Oncology

CureLab Oncology Inc., headquartered in the greater Boston area, Massachusetts, is a clinical-stage biotech company on the verge of an initial public offering (pre-IPO). The company is focused on developing new and safer therapies for solid tumors and other oncological and inflammatory conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!